Henry Schein (NASDAQ:HSIC) Lowered to Hold Rating by Baird R W

Baird R W cut shares of Henry Schein (NASDAQ:HSIC - Free Report) from a strong-buy rating to a hold rating in a research report report published on Monday morning,Zacks.com reports.

Several other research firms have also weighed in on HSIC. Robert W. Baird reiterated a "neutral" rating and set a $72.00 price objective (down previously from $82.00) on shares of Henry Schein in a research note on Monday. Wells Fargo & Company reduced their price target on shares of Henry Schein from $80.00 to $75.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Wall Street Zen lowered Henry Schein from a "buy" rating to a "hold" rating in a report on Thursday, April 17th. Leerink Partners set a $75.00 price objective on Henry Schein in a research note on Monday. Finally, Piper Sandler cut their price target on shares of Henry Schein from $83.00 to $77.00 and set an "overweight" rating on the stock in a report on Wednesday, April 30th. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $78.36.

Henry Schein Stock Down 0.1%

NASDAQ:HSIC traded down $0.04 during mid-day trading on Monday, hitting $70.64. The company had a trading volume of 4,111,040 shares, compared to its average volume of 1,543,471. The firm has a market capitalization of $8.60 billion, a price-to-earnings ratio of 14.76, a PEG ratio of 2.28 and a beta of 0.87. The company has a current ratio of 1.38, a quick ratio of 0.75 and a debt-to-equity ratio of 0.50. Henry Schein has a 1 year low of $60.56 and a 1 year high of $82.49. The business has a fifty day simple moving average of $71.56 and a 200-day simple moving average of $71.33.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.11 by $0.04. Henry Schein had a net margin of 3.21% and a return on equity of 14.87%. The business had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.24 billion. During the same period last year, the business earned $1.10 EPS. The business's revenue was down .1% on a year-over-year basis. Equities analysts forecast that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Henry Schein

Several large investors have recently bought and sold shares of HSIC. JPMorgan Chase & Co. raised its position in Henry Schein by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 6,373,036 shares of the company's stock worth $436,489,000 after purchasing an additional 390,399 shares in the last quarter. Invesco Ltd. raised its stake in shares of Henry Schein by 0.4% in the fourth quarter. Invesco Ltd. now owns 4,963,409 shares of the company's stock valued at $343,468,000 after acquiring an additional 17,552 shares during the last quarter. FMR LLC boosted its holdings in shares of Henry Schein by 6.6% in the 4th quarter. FMR LLC now owns 3,498,033 shares of the company's stock worth $242,064,000 after acquiring an additional 217,143 shares in the last quarter. Geode Capital Management LLC grew its position in Henry Schein by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,169,033 shares of the company's stock worth $218,762,000 after acquiring an additional 14,876 shares during the last quarter. Finally, Palestra Capital Management LLC acquired a new stake in Henry Schein during the 4th quarter valued at $182,988,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.